Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Pharmaceuticals Announces Public Offering of Common Stock
RADNOR, Pa., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  The offering is subject to market conditions, and there can be...
View HTML
Toggle Summary Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone
Substantial and Durable Anti-Seizure Efficacy Shown in Patients Suffering From Severe,  Rare Genetic Epilepsy Marinus to Host Conference Call and Webcast Today at 9:00 am EDT RADNOR, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) --   Marinus Pharmaceuticals, Inc....
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results
Data from Studies in Rare Pediatric Epilepsies and Severe Postpartum Depression Expected in 2 nd Half On-track to Initiate Two Additional Phase 2 Trials Later This Year in Status Epilepticus and Moderate Postpartum Depression RADNOR, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals,...
View HTML
Toggle Summary FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder
RADNOR, Pa., June 29, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S....
View HTML
Toggle Summary Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression
Program to Evaluate Intravenous and Oral Ganaxolone in Patients with Severe or Moderate Postpartum Depression RADNOR, Pa., June 27, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat...
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results
RADNOR, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its...
View HTML
Toggle Summary Marinus to present Ganaxolone DATA at American academy of neurology annual meeting
Platform Presentation of Phase 2 Data in Fragile X Syndrome RADNOR, Pa., April 18, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced...
View HTML
Toggle Summary Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer
RADNOR, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Lorianne K....
View HTML
Toggle Summary Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference
RADNOR, Pa., April 10, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented Phase 1 clinical data showing the safety and tolerability of...
View HTML
Toggle Summary Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference
RADNOR, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward F....
View HTML